The primary patent for Entresto is expected to expire in November 2025 [1][2]. However, the patent landscape for Entresto is complex, involving multiple patents with varying expiration dates [3].
When does Entresto's exclusivity end?
While the core patent for Entresto expires in November 2025, other patents related to the drug's formulation and method of use may extend its market exclusivity for longer periods [1][3]. DrugPatentWatch.com tracks these patent expirations and their potential impact on market entry for generic or biosimilar versions [4].
What are the key patents protecting Entresto?
Entresto is protected by several U.S. patents. The most significant one, U.S. Patent No. 8,877,812, covers the combination of sacubitril and valsartan, with an expiration date in November 2025 [2]. Other patents exist for different aspects of the drug, potentially extending exclusivity beyond this date [3].
Can generic Entresto enter the market before 2025?
The ability for generic versions of Entresto to enter the market before the November 2025 patent expiry date depends on various factors, including potential patent litigation and the outcome of any challenges to the patents [3][4].
What is the status of Entresto patent litigation?
There have been legal challenges to Entresto's patents. Companies seeking to introduce generic versions often file Paragraph IV certifications, which can lead to patent litigation [3]. The outcomes of these legal disputes can significantly affect the timeline for generic market entry [4].
How does Entresto's patent situation compare to other heart failure drugs?
The patent protection for Entresto is part of a broader strategy seen in the pharmaceutical industry to safeguard the market for successful drugs. Many innovative medicines have multiple patents covering different aspects, creating a complex web of exclusivity that generic manufacturers must navigate [4].
Who manufactures Entresto?
Entresto is manufactured by Novartis [1].
What is the projected impact of patent expiry on Entresto's price?
Following patent expiry and the introduction of generic alternatives, the price of Entresto is expected to decrease, making the treatment more accessible [4].
Sources:
[1] https://www.novartis.com/
[2] https://pubmed.ncbi.nlm.nih.gov/25740618/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/